Skip to content
Menu

Tyra Biosciences, Inc. TYRA

Full chart Compare
Set alert

Price alert · TYRA

All alert types
19.73 USD +0.12 (+0.61%)

Regular-session close

20.20 +0.47 +2.38%

After hours · Nov 19, 5:26 PM ET

19.26 Day range 20.18
16.86 52-week range 40.65
YTD
-24.95%
1 year
+18.71%

 

No chart data for this range yet.
Market cap
1.36B
EPS (ttm)
-2.63
Shares out
69.08M
Forward P/E
-6.68
YTD return
-24.95%
1-year return
+18.71%
50-day average
21.38
200-day average
29.24
Enterprise value
659.63M
Price / book
1.96
Volume
346.57K
Avg volume
852.62K
Open
19.63
Previous close
19.61
Day's range
19.26 – 20.18
52-week range
16.86 – 40.65
Beta
0.67
Analysts
Strong Buy
Price target
47.45 (+140.5%)
Earnings date
Mar 1, 2027

Key statistics

Free cash flow
-66.89M
Total cash
700.55M
Total debt
5.46M
Return on equity
-34.89%
Short % of float
23.75%

Fundamental scorecard

4 of 25 checks passed on TYRA’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TYRA Revenue — quarterly 0
TYRA Net income — quarterly -51.12M
TYRA EPS — quarterly -0.74

Earnings

TYRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 1, 2027Dec 30, 2026-0.71———
Nov 10, 2026Sep 30, 2026-0.66867-0.74-0.07-10.67%
Aug 4, 2026Jun 30, 2026-0.64989-0.69-0.04-6.17%
May 13, 2026Mar 31, 2026-0.60-0.64-0.04-6.67%
Mar 2, 2026Dec 31, 2025-0.54-0.57-0.03-5.56%
Nov 5, 2025Sep 30, 2025-0.50-0.500.000.00%

Upgrades / downgrades

TYRA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026WedbushmainOutperformOutperform
Nov 11, 2026HC Wainwright & Co.mainBuyBuy
Sep 22, 2026OppenheimerreitOutperformOutperform
Sep 22, 2026HC Wainwright & Co.mainBuyBuy
Sep 10, 2026WedbushreitOutperformOutperform
Sep 10, 2026HC Wainwright & Co.mainBuyBuy

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
tyra.bio

News

Your note

Sign in to keep a note on TYRA — it syncs with the Stock Master app.

Insider holders

TYRA insider holders
InsiderRelationLatest transactionDateShares held
ASHAR BHAVESHChief Operating OfficerStock Award(Grant)May 4, 202615,013
BENSEN DANIELOfficerSaleFeb 11, 2026146,981
FUHRMAN ALAN CPAChief Financial OfficerStock Award(Grant)May 4, 202636,164
HARRIS TODD JAMESChief Executive OfficerStock Award(Grant)May 4, 20261,437,630
KAPLAN GILLADirectorConversion of Exercise of derivative securityMar 25, 202628,231
KJELLSON NINA SDirectorSaleFeb 4, 20250

Institution ownership

TYRA institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.17.66%12,198,625240.68MSep 29, 2026
FMR, LLC15.25%10,538,463207.92MSep 29, 2026
Janus Henderson Group Ltd.7.62%5,261,720103.81MSep 29, 2026
BVF Inc.6.10%4,215,88683.18MSep 29, 2026
Alta Partners Management Company, L.P. 5.53%3,823,42575.44MSep 29, 2026
Paradigm Biocapital Advisors LP5.08%3,510,36069.26MSep 29, 2026

Fund ownership

TYRA fund ownership
Holder% heldSharesValueReported
Fidelity Securities Fund-Fidelity OTC Portfolio4.80%3,317,03665.45MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.67%1,154,85522.79MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.64%1,135,47222.40MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.38%956,77318.88MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund1.26%871,83117.20MOct 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.15%793,14015.65MJun 29, 2026